IRVINE, CA--(Marketwire - April 15, 2010) - BIOLASE Technology, Inc. (NASDAQ: BLTI), the world’s leading dental laser company, today announced that it was awarded a new patent (U.S. Patent number 7,697,814) related to its new handpiece with spatially controllable output energy distributions for teeth whitening and pain management. The handpiece is utilized with the BIOLASE family of diode laser systems.
The patent, granted on April 14, 2010, has broad coverage for a therapeutic laser handpiece applicable to BIOLASE’s diode family of laser products, including the ezlase™, Diolase™ and iLase™. The specific therapeutic applications covered by the claims are: teeth whitening, caries prevention and detection, desensitizing teeth, pain reduction for degenerative arthritis, rheumatoid arthritis, muscle pain, tendonitis, acute soft tissue pain, treatment of muscle tears, treatment of hematomas, treatment of shingles, scarring, burn healing, wound healing, and composite curing.
David M. Mulder, Chief Executive Officer of BIOLASE, stated, “Our goal is to provide a total diode solution for dentists and other medical professionals. This patent helps us continue to establish our laser systems as essential tools in dentistry, to continue to build a leading position in the dental laser market, and to provide laser solutions that go into broader medical fields. Providing advanced technologies that allow dentists to perform simple or complex cosmetic dental procedures with minimal trauma, improving patient acceptance and clinically superior results, and providing low cost laser solutions for multiple medical professions will help us achieve this. We believe we have superior products in our family of diode lasers and are pleased to expand and strengthen our protection of these products through this additional patent.”
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc. (http://www.biolase.com), the world’s leading dental laser company, develops, manufactures and markets Waterlase technology and lasers and related products that advance the practice of dentistry and medicine. The Company’s products incorporate patented and patent pending technologies designed to provide clinically superior performance with reduced pain and faster recovery times. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology, pain management and other medical and consumer markets.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company’s actual results to differ materially from the statements contained herein, and are described in the Company’s reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
For further information, please contact: Jill Bertotti (investors) and Len Hall (media), of Allen & Caron, +1-949-474-4300
